Premium
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)
Author(s) -
YAHR MELVIN D.,
MENDOZA MARINA R.,
MOROS DANIEL,
BERGMANN KENNETH J.
Publication year - 1983
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1983.tb01521.x
Subject(s) - selegiline , levodopa , parkinsonism , medicine , decarboxylase inhibitor , parkinson's disease , dopaminergic , anticholinergic , disease , pharmacology , dopamine
— There are at present numerous pharmacological agents available for the control of parkinson symptoms. None are ideal; all have their limitations. The most potent is levodopa administered with a peripheral decarboxylase inhibitor. However, because its effectiveness declines after long‐term use and side effects increase in severity, it should be reserved for individuals with established symptoms which are functionally impairing. In patients with minimal symptoms, anticholinergic agents, or agents which facilitate dopaminergic mechanisms normally operative in the nervous system, should be used. In a limited trial, deprenyl has produced promising results during this phase of parkinsonism. Deprenyl's major usefulness however, has been demonstrated in patients under treatment with levodopa which has become complicated by fluctuating responses – particularly those of the end‐start‐dose variety. In such patients, it is possible to achieve an increase in “on” time and a decrease in the severity of parkinsonism. In most patients, such a response can maintained for a period of two years or longer.